Modeling glioblastoma complexity with organoids for personalized treatments

Kristen D. Pawlowski; Joseph T. Duffy; Maria V. Babak; Irina V. Balyasnikova

doi:10.1016/j.molmed.2023.01.002

Modeling glioblastoma complexity with organoids for personalized treatments

Kristen D. Pawlowski, Joseph T. Duffy, Maria V. Babak^*, Irina V. Balyasnikova

^*Corresponding author for this work

Neurological Surgery

Research output: Contribution to journal › Review article › peer-review

15 Scopus citations

Abstract

Glioblastoma (GBM) remains a fatal diagnosis despite the current standard of care of maximal surgical resection, radiation, and temozolomide (TMZ) therapy. One aspect that impedes drug development is the lack of an appropriate model representative of the complexity of patient tumors. Brain organoids derived from cell culture techniques provide a robust, easily manipulatable, and high-throughput model for GBM. In this review, we highlight recent progress in developing GBM organoids (GBOs) with a focus on generating the GBM microenvironment (i.e., stem cells, vasculature, and immune cells) recapitulating human disease. Finally, we also discuss the use of organoids as a screening tool in drug development for GBM.

Original language	English (US)
Pages (from-to)	282-296
Number of pages	15
Journal	Trends in Molecular Medicine
Volume	29
Issue number	4
DOIs	https://doi.org/10.1016/j.molmed.2023.01.002
State	Published - Apr 2023

Funding

The authors are grateful to Tibor Hajsz for helping to generate artwork. This study was supported by the NINDS R01 NS122395 (I.V.B.) and NCI R01CA257958 (I.V.B.). M.V.B. acknowledges the financial support from the City University of Hong Kong (Project Nos. 9610518 and 7005614 ).

Keywords

brain organoids
drug screening
glioblastoma
tumor microenvironment

ASJC Scopus subject areas

Molecular Medicine
Molecular Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.molmed.2023.01.002

Cite this

@article{d0877d31a5214ef5b1684b9c66b0fd78,

title = "Modeling glioblastoma complexity with organoids for personalized treatments",

abstract = "Glioblastoma (GBM) remains a fatal diagnosis despite the current standard of care of maximal surgical resection, radiation, and temozolomide (TMZ) therapy. One aspect that impedes drug development is the lack of an appropriate model representative of the complexity of patient tumors. Brain organoids derived from cell culture techniques provide a robust, easily manipulatable, and high-throughput model for GBM. In this review, we highlight recent progress in developing GBM organoids (GBOs) with a focus on generating the GBM microenvironment (i.e., stem cells, vasculature, and immune cells) recapitulating human disease. Finally, we also discuss the use of organoids as a screening tool in drug development for GBM.",

keywords = "brain organoids, drug screening, glioblastoma, tumor microenvironment",

author = "Pawlowski, {Kristen D.} and Duffy, {Joseph T.} and Babak, {Maria V.} and Balyasnikova, {Irina V.}",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier Ltd",

year = "2023",

month = apr,

doi = "10.1016/j.molmed.2023.01.002",

language = "English (US)",

volume = "29",

pages = "282--296",

journal = "Trends in Molecular Medicine",

issn = "1471-4914",

publisher = "Elsevier Ltd",

number = "4",

}

TY - JOUR

T1 - Modeling glioblastoma complexity with organoids for personalized treatments

AU - Pawlowski, Kristen D.

AU - Duffy, Joseph T.

AU - Babak, Maria V.

AU - Balyasnikova, Irina V.

PY - 2023/4

Y1 - 2023/4

N2 - Glioblastoma (GBM) remains a fatal diagnosis despite the current standard of care of maximal surgical resection, radiation, and temozolomide (TMZ) therapy. One aspect that impedes drug development is the lack of an appropriate model representative of the complexity of patient tumors. Brain organoids derived from cell culture techniques provide a robust, easily manipulatable, and high-throughput model for GBM. In this review, we highlight recent progress in developing GBM organoids (GBOs) with a focus on generating the GBM microenvironment (i.e., stem cells, vasculature, and immune cells) recapitulating human disease. Finally, we also discuss the use of organoids as a screening tool in drug development for GBM.

AB - Glioblastoma (GBM) remains a fatal diagnosis despite the current standard of care of maximal surgical resection, radiation, and temozolomide (TMZ) therapy. One aspect that impedes drug development is the lack of an appropriate model representative of the complexity of patient tumors. Brain organoids derived from cell culture techniques provide a robust, easily manipulatable, and high-throughput model for GBM. In this review, we highlight recent progress in developing GBM organoids (GBOs) with a focus on generating the GBM microenvironment (i.e., stem cells, vasculature, and immune cells) recapitulating human disease. Finally, we also discuss the use of organoids as a screening tool in drug development for GBM.

KW - brain organoids

KW - drug screening

KW - glioblastoma

KW - tumor microenvironment

UR - http://www.scopus.com/inward/record.url?scp=85148742272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85148742272&partnerID=8YFLogxK

U2 - 10.1016/j.molmed.2023.01.002

DO - 10.1016/j.molmed.2023.01.002

M3 - Review article

C2 - 36805210

AN - SCOPUS:85148742272

SN - 1471-4914

VL - 29

SP - 282

EP - 296

JO - Trends in Molecular Medicine

JF - Trends in Molecular Medicine

IS - 4

ER -

Modeling glioblastoma complexity with organoids for personalized treatments

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this